SC
CRSP icon

Scotia Capital’s CRISPR Therapeutics CRSP Stock Holding History

Scotia Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15,234
Closed -$987K – 906
2025
Q3 		$987K Sell
15,234
-278
-2% -$16K ﹤0.01% 566
2025
Q2 		$754K Buy
15,512
+569
+4% +$22K ﹤0.01% 569
2025
Q1 		$509K Buy
14,943
+2,648
+22% +$112K ﹤0.01% 616
2024
Q4 		$484K Buy
12,295
+1,300
+12% +$61.4K ﹤0.01% 628
2024
Q3 		$517K Buy
10,995
+40
+0.4% +$2.03K ﹤0.01% 612
2024
Q2 		$592K Sell
10,955
-670
-6% -$38.8K ﹤0.01% 581
2024
Q1 		$792K Buy
11,625
+545
+5% +$39K ﹤0.01% 533
2023
Q4 		$694K Buy
11,080
+1,864
+20% +$103K ﹤0.01% 525
2023
Q3 		$418K Sell
9,216
-412
-4% -$21.3K ﹤0.01% 583
2023
Q2 		$541K Buy
+9,628
New +$546K ﹤0.01% 542
2021
Q3 		– Sell
-1,399
Closed -$226K – 857
2021
Q2 		$226K Buy
+1,399
New +$170K ﹤0.01% 761

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
GP
GSK plc London $602M AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Scotia Capital's CRSP Position: Q4 2025 in Review

Scotia Capital sold out of CRISPR Therapeutics (CRSP) in Q4 2025, closing a stake of 15,234 shares — an estimated $987K sold.

Scotia Capital first reported a position in CRSP in Q2 2021 and held it in 11 quarters. The position peaked at $987K in Q3 2025. 480 funds tracked by Wall St. Rank hold CRSP as of Q4 2025.

  • Scotia Capital reported no remaining CRISPR Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Scotia Capital sold 15,234 CRISPR Therapeutics shares in Q4 2025, an estimated $987K.
  • Scotia Capital first reported a position in CRISPR Therapeutics in Q2 2021 and held it in 11 quarters.
  • Scotia Capital's CRISPR Therapeutics position peaked at $987K in Q3 2025.
  • 480 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2025.

Based on Scotia Capital's 13F filing for Q4 2025, filed 12 Feb 2026.